Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
lisaftoclax (APG-2575)
i
Other names:
APG-2575, APG2575, APG 2575
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(7)
News
Twitter
Trials
Company:
Ascentage Pharma
Drug class:
Bcl2 inhibitor
Related drugs:
‹
venetoclax (383)
paclitaxel (163)
albumin-bound paclitaxel (57)
ABT 263 (16)
APG-1252 (6)
micellar paclitaxel (3)
APG1244 (2)
BGB-11417 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
venetoclax (383)
paclitaxel (163)
albumin-bound paclitaxel (57)
ABT 263 (16)
APG-1252 (6)
micellar paclitaxel (3)
APG1244 (2)
BGB-11417 (1)
paclitaxel oral (1)
oral paclitaxel/encequidar (1)
AT 101 (1)
S55746 (1)
›
Associations
(7)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
Chr amplification(1)(q21)
Multiple Myeloma
Chr amplification(1)(q21)
Multiple Myeloma
lenalidomide + APG-2575
Sensitive: D – Preclinical
lenalidomide + APG-2575
Sensitive
:
D
lenalidomide + APG-2575
Sensitive: D – Preclinical
lenalidomide + APG-2575
Sensitive
:
D
Chr t(11;14)
Multiple Myeloma
Chr t(11;14)
Multiple Myeloma
APG-2575
Sensitive: D – Preclinical
APG-2575
Sensitive
:
D
APG-2575
Sensitive: D – Preclinical
APG-2575
Sensitive
:
D
BCL2 overexpression + MCL1 overexpression
Diffuse Large B Cell Lymphoma
BCL2 overexpression + MCL1 overexpression
Diffuse Large B Cell Lymphoma
ibrutinib + APG-2575
Sensitive: D – Preclinical
ibrutinib + APG-2575
Sensitive
:
D
ibrutinib + APG-2575
Sensitive: D – Preclinical
ibrutinib + APG-2575
Sensitive
:
D
BCL2 overexpression + MCL1 expression
Diffuse Large B Cell Lymphoma
BCL2 overexpression + MCL1 expression
Diffuse Large B Cell Lymphoma
APG-115 + APG-2575
Sensitive: D – Preclinical
APG-115 + APG-2575
Sensitive
:
D
APG-115 + APG-2575
Sensitive: D – Preclinical
APG-115 + APG-2575
Sensitive
:
D
BCL2 overexpression
Diffuse Large B Cell Lymphoma
BCL2 overexpression
Diffuse Large B Cell Lymphoma
APG-2575
Sensitive: D – Preclinical
APG-2575
Sensitive
:
D
APG-2575
Sensitive: D – Preclinical
APG-2575
Sensitive
:
D
ER positive
Estrogen Receptor Positive Breast Cancer
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib + APG-2575
Sensitive: D – Preclinical
palbociclib + APG-2575
Sensitive
:
D
palbociclib + APG-2575
Sensitive: D – Preclinical
palbociclib + APG-2575
Sensitive
:
D
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
olverembatinib + APG-2575
Sensitive: D – Preclinical
olverembatinib + APG-2575
Sensitive
:
D
olverembatinib + APG-2575
Sensitive: D – Preclinical
olverembatinib + APG-2575
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login